

# Dee Shortridge

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2976983/publications.pdf>

Version: 2024-02-01

48  
papers

1,858  
citations

257450

24  
h-index

276875

41  
g-index

48  
all docs

48  
docs citations

48  
times ranked

2262  
citing authors

#	ARTICLE	IF	CITATIONS
1	<i>In Vitro</i> Activity of Cefiderocol against U.S. and European Gram-Negative Clinical Isolates Collected in 2020 as Part of the SENTRY Antimicrobial Surveillance Program. <i>Microbiology Spectrum</i> , 2022, 10, e0271221.	3.0	34
2	Antimicrobial activity of dalbavancin against Gram-positive bacteria isolated from patients hospitalized with bloodstream infection in United States and European medical centers (2018–2020). <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2022, 41, 867-873.	2.9	5
3	Multicenter Evaluation of the Novel ETEST Fosfomycin for Antimicrobial Susceptibility Testing of Enterobacterales, <i>Enterococcus faecalis</i> , and <i>Staphylococcus</i> Species. <i>Journal of Clinical Microbiology</i> , 2022, 60, .	3.9	4
4	Susceptibility trends of ceftolozane/tazobactam and comparators when tested against U.S. gram-negative bacterial surveillance isolates (2012–2018). <i>Diagnostic Microbiology and Infectious Disease</i> , 2021, 100, 115302.	1.8	8
5	Activity of meropenem/vaborbactam and comparators against Gram-negative isolates from Eastern and Western European patients hospitalized with pneumonia including ventilator-associated pneumonia (2014–19). <i>Journal of Antimicrobial Chemotherapy</i> , 2021, 76, 2600-2605.	3.0	21
6	Minocycline Activity against Unusual Clinically Significant Gram-Negative Pathogens. <i>Antimicrobial Agents and Chemotherapy</i> , 2021, 65, e0126421.	3.2	3
7	Ceftolozane-tazobactam activity against clinical isolates of <i>Pseudomonas aeruginosa</i> from ICU patients with pneumonia: United States, 2015–2018. <i>International Journal of Infectious Diseases</i> , 2021, 112, 321-326.	3.3	9
8	Surveillance of omadacycline activity tested against clinical isolates from the USA: report from the SENTRY Antimicrobial Surveillance Program, 2019. <i>Journal of Global Antimicrobial Resistance</i> , 2021, 27, 337-351.	2.2	13
9	Antimicrobial activity of ceftolozane/tazobactam tested against contemporary (2015–2017) <i>Pseudomonas aeruginosa</i> isolates from a global surveillance programme. <i>Journal of Global Antimicrobial Resistance</i> , 2020, 21, 60-64.	2.2	22
10	Activity of Meropenem-Vaborbactam against Bacterial Isolates Causing Pneumonia in Patients in U.S. Hospitals during 2014 to 2018. <i>Antimicrobial Agents and Chemotherapy</i> , 2020, 64, .	3.2	23
11	Update on the activity of delafloxacin against acute bacterial skin and skin-structure infection isolates from European hospitals (2014–2019). <i>Journal of Global Antimicrobial Resistance</i> , 2020, 23, 278-283.	2.2	5
12	Antimicrobial Activity of Ceftolozane-Tazobactam and Comparators against Clinical Isolates of <i>Haemophilus influenzae</i> from the United States and Europe. <i>Antimicrobial Agents and Chemotherapy</i> , 2020, 64, .	3.2	2
13	Activity of ceftolozane-tazobactam and comparators when tested against bacterial surveillance isolates collected from patients at risk of infections caused by resistant gram-negative pathogens. <i>Diagnostic Microbiology and Infectious Disease</i> , 2020, 98, 115101.	1.8	3
14	Surveillance of Omadacycline Activity Tested against Clinical Isolates from the United States and Europe: Report from the SENTRY Antimicrobial Surveillance Program, 2016 to 2018. <i>Antimicrobial Agents and Chemotherapy</i> , 2020, 64, .	3.2	32
15	Meropenem-Vaborbactam Activity against Carbapenem-Resistant <i>Enterobacterales</i> Isolates Collected in U.S. Hospitals during 2016 to 2018. <i>Antimicrobial Agents and Chemotherapy</i> , 2020, 64, .	3.2	44
16	Activity of fosfomycin when tested against US contemporary bacterial isolates. <i>Diagnostic Microbiology and Infectious Disease</i> , 2019, 93, 143-146.	1.8	16
17	<i>In Vitro</i> Activity of Minocycline against U.S. Isolates of <i>Acinetobacter baumannii</i> - <i>Acinetobacter calcoaceticus</i> Species Complex, <i>Stenotrophomonas maltophilia</i> , and <i>Burkholderia cepacia</i> Complex: Results from the SENTRY Antimicrobial Surveillance Program, 2014 to 2018. <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 63, .	3.2	30
18	Comparison of the In Vitro Susceptibility of Ceftolozane-Tazobactam With the Cumulative Susceptibility Rates of Standard Antibiotic Combinations When Tested Against <i>Pseudomonas aeruginosa</i> From ICU Patients With Bloodstream Infections or Pneumonia. <i>Open Forum Infectious Diseases</i> , 2019, 6, ofz240.	0.9	8

#	ARTICLE	IF	CITATIONS
19	Activity of tedizolid against gram-positive clinical isolates causing infections in Europe and surrounding areas (2014–2015). <i>Journal of Chemotherapy</i> , 2019, 31, 188-194.	1.5	18
20	Geographic and Temporal Patterns of Antimicrobial Resistance in <i>Pseudomonas aeruginosa</i> Over 20 Years From the SENTRY Antimicrobial Surveillance Program, 1997–2016. <i>Open Forum Infectious Diseases</i> , 2019, 6, S63-S68.	0.9	84
21	Twenty-Year Trends in Antimicrobial Susceptibilities Among <i>Staphylococcus aureus</i> From the SENTRY Antimicrobial Surveillance Program. <i>Open Forum Infectious Diseases</i> , 2019, 6, S47-S53.	0.9	132
22	Surveillance of omadacycline activity tested against clinical isolates from the United States and Europe: Results from the SENTRY Antimicrobial Surveillance Programme, 2017. <i>Journal of Global Antimicrobial Resistance</i> , 2019, 19, 56-63.	2.2	33
23	Evaluation of the Bactericidal Activity of Fosfomycin in Combination with Selected Antimicrobial Comparison Agents Tested against Gram-Negative Bacterial Strains by Using Time-Kill Curves. <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 63, .	3.2	35
24	Comparative In Vitro Activities of New Antibiotics for the Treatment of Skin Infections. <i>Clinical Infectious Diseases</i> , 2019, 68, S200-S205.	5.8	5
25	Activity of ceftolozane-tazobactam and comparators when tested against Gram-negative isolates collected from paediatric patients in the USA and Europe between 2012 and 2016 as part of a global surveillance programme. <i>International Journal of Antimicrobial Agents</i> , 2019, 53, 637-643.	2.5	19
26	Ceftobiprole activity when tested against contemporary bacteria causing bloodstream infections in the United States (2016–2017). <i>Diagnostic Microbiology and Infectious Disease</i> , 2019, 94, 304-313.	1.8	19
27	Antimicrobial activity of ceftolozane–tazobactam tested against gram-negative contemporary (2015–2017) isolates from hospitalized patients with pneumonia in US medical centers. <i>Diagnostic Microbiology and Infectious Disease</i> , 2019, 94, 93-102.	1.8	39
28	Extensive Gene Amplification as a Mechanism for Piperacillin-Tazobactam Resistance in <i>Escherichia coli</i> . <i>MBio</i> , 2018, 9, .	4.1	54
29	Surveillance of Omadacycline Activity Tested against Clinical Isolates from the United States and Europe as Part of the 2016 SENTRY Antimicrobial Surveillance Program. <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .	3.2	59
30	Activity of Ceftolozane-Tazobactam against <i>Pseudomonas aeruginosa</i> and Enterobacteriaceae Isolates Collected from Respiratory Tract Specimens of Hospitalized Patients in the United States during 2013 to 2015. <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .	3.2	46
31	Antimicrobial Activity of Ceftolozane-Tazobactam Tested Against <i>Enterobacteriaceae</i> and <i>Pseudomonas aeruginosa</i> with Various Resistance Patterns Isolated in U.S. Hospitals (2013–2016) as Part of the Surveillance Program: Program to Assess Ceftolozane-Tazobactam Susceptibility. <i>Microbial Drug Resistance</i> , 2018, 24, 563-577.	2.0	48
32	Antimicrobial Activities of Aztreonam-Avibactam and Comparator Agents against Contemporary (2016) Clinical Enterobacteriaceae Isolates. <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .	3.2	61
33	Antimicrobial activity of ceftolozane-tazobactam tested against Enterobacteriaceae and <i>Pseudomonas aeruginosa</i> collected from patients with bloodstream infections isolated in United States hospitals (2013–2015) as part of the Program to Assess Ceftolozane-Tazobactam Susceptibility (PACTS) surveillance program. <i>Diagnostic Microbiology and Infectious Disease</i> , 2018, 92, 158-163.	1.8	32
34	Ceftolozane-Tazobactam Activity against <i>Pseudomonas aeruginosa</i> Clinical Isolates from U.S. Hospitals: Report from the PACTS Antimicrobial Surveillance Program, 2012 to 2015. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	3.2	73
35	Correlation between phenotypic antibiotic susceptibility and the resistome in <i>Pseudomonas aeruginosa</i> . <i>International Journal of Antimicrobial Agents</i> , 2017, 50, 210-218.	2.5	65
36	Ceftolozane-tazobactam activity against drug-resistant Enterobacteriaceae and <i>Pseudomonas aeruginosa</i> causing healthcare-associated infections in Latin America: report from an antimicrobial surveillance program (2013–2015). <i>Brazilian Journal of Infectious Diseases</i> , 2017, 21, 627-637.	0.6	35

#	ARTICLE	IF	CITATIONS
37	Antimicrobial Activity of Ceftazidime-Avibactam Tested against Multidrug-Resistant Enterobacteriaceae and <i>Pseudomonas aeruginosa</i> Isolates from U.S. Medical Centers, 2013 to 2016. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	3.2	89
38	In Vitro Evaluation of Delafloxacin Activity when Tested Against Contemporary community-Acquired Bacterial Respiratory Tract Infection Isolates (2014-2016): Results from the SENTRY Antimicrobial Surveillance Program. <i>Open Forum Infectious Diseases</i> , 2017, 4, S369-S369.	0.9	3
39	Activity of Delafloxacin When Tested Against Bacterial Surveillance Isolates Collected in the US and Europe During 2014-2016 as Part of a Global Surveillance Program. <i>Open Forum Infectious Diseases</i> , 2017, 4, S373-S374.	0.9	3
40	Phylogenetic Distribution of CRISPR-Cas Systems in Antibiotic-Resistant <i>Pseudomonas aeruginosa</i> . <i>MBio</i> , 2015, 6, e01796-15.	4.1	217
41	Population Analysis of <i>Escherichia coli</i> Isolates with Discordant Resistance Levels by Piperacillin-Tazobactam Broth Microdilution and Agar Dilution Testing. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 1779-1781.	3.2	18
42	Rapid Clinical Bacteriology and Its Future Impact. <i>Annals of Laboratory Medicine</i> , 2013, 33, 14-27.	2.5	102
43	Correlation of Cefoxitin MICs with the Presence of <i>mecA</i> in <i>Staphylococcus</i> spp. <i>Journal of Clinical Microbiology</i> , 2009, 47, 1902-1905.	3.9	17
44	Detection of Inducible Clindamycin Resistance in Staphylococci by Broth Microdilution Using Erythromycin-Clindamycin Combination Wells. <i>Journal of Clinical Microbiology</i> , 2007, 45, 3954-3957.	3.9	16
45	Antimicrobial Susceptibilities of Invasive Pediatric Abiotrophia and Granulicatella Isolates. <i>Journal of Clinical Microbiology</i> , 2004, 42, 4323-4326.	3.9	44
46	Characterization and Prevalence of MefA, MefE, and the Associated <i>msr (D)</i> Gene in <i>Streptococcus pneumoniae</i> Clinical Isolates. <i>Journal of Clinical Microbiology</i> , 2004, 42, 3570-3574.	3.9	106
47	Comparison of Clarithromycin and Amoxicillin/Clavulanic Acid for Community-Acquired Pneumonia in an Era of Drug-Resistant <i>Streptococcus pneumoniae</i> . <i>Clinical Drug Investigation</i> , 2003, 23, 491-501.	2.2	14
48	Identification of a 23S rRNA Gene Mutation in Clarithromycin-Resistant <i>Helicobacter pylori</i> . <i>Helicobacter</i> , 1996, 1, 227-228.	3.5	90